PYC Therapeutics Limited · ASX:PYC

PYC Therapeutics — Investor Presentation (January 2026)

38 slides from PYC Therapeutics's investor presentation, January 2026

  1. Slide 1: Corporate Presentation

    Life-changing science Corporate Presentation January 2026

  2. Slide 2: Disclaimer

    Disclaimer The purpose of this presentation is to provide an update of the business of PYC Therapeutics about the future, you are urged to view all forward looking statements contained in this Limited (ASX:PYC) [‘PYC’]. These slides have been prepared as a presentation aid only and presentation with

  3. Slide 3: PYC's mission is to create life-changing RNA therapies

    PYC’s mission is to create life-changing RNA therapies that address the root cause of diseases resulting from insufficient gene expression The Company’s work is dedicated to patients who currently have no treatment options available Sierra – living with Phelan- McDermid Syndrome1 PYC THERAPEUTICS 3

  4. Slide 4: An introduction to PYC Therapeutics

    An introduction to PYC Therapeutics Precision medicines PYC is a drug discovery and development company focused on creating life-changing new therapies for patients who have genetic diseases and no treatment options available today Disease-modifying PYC’s strategy is to use RNA therapeutics to incre

  5. Slide 5: PYC has created a pipeline of clinical-stage drug candidates

    PYC has created a pipeline of clinical-stage drug candidates in areas of major unmet need Historical progress Progress expected in 20251 Program Pre-clinical Clinical Prevalence1 Phase 1/2 Registrational PYC-003 Polycystic Kidney Disease 1 in 1,000 PYC-002 Phelan-McDermid Syndrome 1 in 10,000 VP-001

  6. Slide 6: Highlights of PYC's pipeline – drug candidates with best-in-indication potential

    Highlights of PYC’s pipeline – 4 drug candidates with best-in- indication potential1 1 2 3 4 5 Disease-modifying In areas of major With the highest Validated in patient- Generating human drug candidates1 unmet need probability of success derived models data in 2026/2027 Up to 5x Each of PYC’s In a d

  7. Slide 7: PYC will generate human efficacy data over the coming 24 months

    PYC will generate human efficacy data for all 4 of these drug candidates over the coming 24 months1 These data read-outs will highlight the potential of disease-modifying drug candidates in these genetically- defined diseases1 PYC-003 in ADPKD2 PYC-002 in PMS3 VP-001 in RP114 PYC-001 in ADOA5 • Mult

  8. Slide 8: PYC's platform technologies

    Life-changing science PYC’s platform technologies

  9. Slide 9: PYC designs RNA therapies to increase gene expression in haploinsufficiency

    PYC designs RNA therapies to increase gene expression in diseases caused by haploinsufficiency There are two copies of One copy of a gene is PYC’s drug candidates leverage every gene in humans non-functional in a the ‘good’ copy of the gene to haploinsufficiency restore expression1 2.0 Functional Pr

  10. Slide 10: Precision drug design combined with delivery technology

    PYC combines this precision drug design expertise with its delivery technology to harness a new class of RNA therapeutic1 1. Design of RNA therapies 2. Drug delivery platform Inside the cell Outside the cell1 RNA target RNA Therapeutic Binding Inside the cell Peptide RNA Therapeutic RNA therapeutic

  11. Slide 11: PYC uses 'mini-human models' to confirm restoration of gene expression

    1. PYC uses ‘mini-human models’1 to confirm restoration of gene expression in the target cell/organ before entering the clinic PYC uses patient tissue samples to create models of The ability of the drug candidate to restore gene the specific cells affected in the target indication1 expression in the

  12. Slide 12: Gene expression control combined with proprietary drug delivery technology

    2. PYC combines control of gene expression with a proprietary drug delivery technology to reach more target cells PYC validates delivery of each drug candidate in vivo1 Delivery – PYC’s drug candidates reach the target cell at safe and well-tolerated doses in vivo External view of kidney Internal vi

  13. Slide 13: Pipeline with disease-modifying potential in substantial markets

    The result is a pipeline of drug candidates with disease- modifying potential in substantial markets (>US$1bn p.a.)1 Historical progress Progress expected in 20251 Program Pre-clinical Clinical Market Size1 Phase 1/2 Registrational PYC-003 Polycystic Kidney Disease US$10bn p.a. PYC-002 Phelan-McDerm

  14. Slide 14: Autosomal Dominant Polycystic Kidney Disease (PKD) Program

    Life-changing science Autosomal Dominant Polycystic Kidney Disease (PKD) Program January 2026

  15. Slide 15: Patients with PKD require renal transplantation at a median age of 55

    Patients with PKD require renal transplantation at a median age of 551 PKD is characterised by progressive growth of fluid-filled cysts that impair kidney function2 Age 20 40 60 Endpoint Kidney eGFR Function Blood test Total Kidney Kidney Volume (TKV) Size MRI3 1. See: Cornec-Le Gall E, et al. Type

  16. Slide 16: The path to market in PKD incorporates a single combined P2/3 study

    The path to market in PKD incorporates a single combined P2/3 study1 Combined Phase 1a/1b Study2 Phase 2/3 Study Part A - SAD in healthy Part B – SAD in ADPKD Part C – MAD in Registrational study Confirmatory extension volunteers Patients PKD Patients Commercialisation Total Kidney Volume (TKV) 12-m

  17. Slide 17: Immediate objective in PKD is clinical proof of concept

    PYC’s immediate objective in PKD is to demonstrate clinical proof of concept on the registrational endpoint Progress to date Combined Phase 1a/1b Study2 Phase 2/3 Study Part A - SAD in healthy Part B – SAD in ADPKD Part C – MAD in Registrational study Confirmatory extension volunteers Patients PKD P

  18. Slide 18: Human safety and pre-clinical efficacy data in PKD

    Human safety and pre-clinical efficacy data illustrate the potential for impact in this indication1,2 ✱✱✱✱ 2.0 ✱✱✱✱ ✱✱✱✱ Untreated Human safety: PYC-003 Healthy volunteers and patients PC1 Fold Change over Untreated ✱✱ 1.5 Normalised to Total Protein Pre-clinical efficacy: Increased target 1.0 PYC-0

  19. Slide 19: PYC-003 is progressing towards a major unmet patient need

    PYC-003 is progressing towards a major unmet patient need Standard of care (Tolvaptan) is used by <7% of the addressable patient population1 • Despite limited patient uptake, 2023 sales of Tolvaptan exceeded US$1.5bn1 Estimated number of patients with PKD due USA Europe Japan >100,000 >150,000 >20,0

  20. Slide 20: Phelan-McDermid Syndrome (PMS) Program

    Life-changing science Phelan-McDermid Syndrome (PMS) Program January 2026

  21. Slide 21: Patients with PMS experience life-long disability

    Patients with Phelan-McDermid Syndrome (PMS) experience life-long disability PMS is characterised by severe intellectual and physical developmental delays1,2 Sierra – living with PMS3 Age 0 5 10 15+ Intellectual disability Speech and developmental delays Skills regression Symptoms Neuropsychiatric a

  22. Slide 22: PYC-002 follows an established clinical development pathway

    PYC-002 follows an established clinical development pathway1,2 Pre-clinical studies GLP. PK and Toxicology Studies Clinical Trials For this combination of: • Chemistry: 2ʹMOE PS3 Clinical validation of this modality via the same route of • Administration: intrathecal administration has been establis

  23. Slide 23: Immediate objective in PMS is to complete GLP toxicology studies

    PYC’s immediate objective in PMS is to complete GLP toxicology studies enabling ‘first in human’ trials to commence Progress to date Pre-clinical studies GLP. PK and Toxicology Studies Clinical Trials For this combination of: • Chemistry: 2ʹMOE PS3 Clinical validation of this modality via the same r

  24. Slide 24: Pre-clinical efficacy data illustrate disease-modifying potential

    Pre-clinical efficacy data illustrate the disease-modifying potential of this drug candidate1 PYC-002 quantitatively restores SHANK3 protein PYC-002 reaches the target cell and modulates gene expression in PMS patient-derived models in vitro1 expression at safe and well-tolerated doses in vivo1 2-fo

  25. Slide 25: PYC-002 is progressing towards a major unmet patient need

    PYC-002 is progressing towards a major unmet patient need Estimated USA Europe Japan prevalence of 20,000 20,000 5,000 PMS1 PYC THERAPEUTICS 25 1. PMS Foundation

  26. Slide 26: Retinitis Pigmentosa type 11 (RP11) Program

    Life-changing science Retinitis Pigmentosa type 11 (RP11) Program January 2026

  27. Slide 27: Patients with RP11 experience progressive and irreversible vision loss

    Patients with RP11 experience progressive and irreversible vision loss beginning in childhood1-3 Illustration of the degeneration in sight experienced by an RP11 patient1-3 6 years old 26 years old 46 years old Patients experience night blindness followed by loss of peripheral and then central visio

  28. Slide 28: PYC expects to initiate the first registrational study in RP11 in 2026

    PYC expects to initiate the first registrational study in RP11 in 20261 VP-001 is the first clinical-stage drug candidate for RP112 FDA Type D meeting Q1 20261 Open Phase 1a SAD Label Phase 1b MAD Study Phase 2/3 Study Extension • Safety & Tolerability NDA • Safety & Tolerability • Efficacy • Effica

  29. Slide 29: Immediate objective is to align on the pathway to an NDA in RP11

    PYC’s immediate objective is to align on the pathway to an NDA in RP11 PYC’s immediate objective FDA Type D meeting Q1 20261 Progress to date Open Phase 1a SAD Label Phase 1b MAD Study Phase 2/3 Study Extension • Safety & Tolerability NDA • Safety & Tolerability • Efficacy • Efficacy • Primary: • Lo

  30. Slide 30: Human safety and efficacy data in RP11

    Human safety and efficacy data illustrate the potential of this drug candidate in RP111 Human safety: Human efficacy: RP11 patients Change in Low-Luminance Visual Acuity (LLVA) in RP11 patients2,3 • No Treatment Related- 20 Serious Adverse events Change from baseline in LLVA 15 observed in any subje

  31. Slide 31: VP-001 is progressing towards a major unmet patient need

    VP-001 is progressing towards a major unmet patient need Estimated USA Europe Japan prevalence of 3,000 3,000 1,200 RP111 PYC THERAPEUTICS 31 1. See: Sullivan L, et al. Genomic rearrangements of the PRPF31 gene account for 2.5% of autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2

  32. Slide 32: Autosomal Dominant Optic Atrophy (ADOA) Program

    Life-changing science Autosomal Dominant Optic Atrophy (ADOA) Program January 2026

  33. Slide 33: Patients with ADOA experience progressive and irreversible vision loss

    Patients with ADOA experience progressive and irreversible vision loss beginning in childhood1-3 Degenerative sight of an ADOA patient1-3 10 years old 30 years old 50 years old ADOA is the most common inherited optic neuropathy – the median age of onset at 7 years of age2 1. Lenaers G, et al. Domina

  34. Slide 34: PYC's drug candidate could become the first approved treatment for ADOA

    PYC’s drug candidate has the potential to become the first approved treatment for patients with ADOA1 Phase 1a SAD Study Phase 1b MAD Study2 Phase 2/3 Study Cohorts 60 mcg 60 mcg (Q12W) Objectives of Phase 1/2/3 trials of PYC-001 • Safety & Tolerability • Efficacy 30 mcg 30 mcg (Q8W, Q12W) • Visual

  35. Slide 35: Immediate objective is to demonstrate clinical proof of concept

    PYC’s immediate objective in this drug development program is to demonstrate ‘clinical proof of concept’ Progress to date Phase 1a SAD Study Phase 1b MAD Study2 Phase 2/3 Study Cohorts 60 mcg 60 mcg (Q12W) Objectives of Phase 1/2/3 trials of PYC-001 • Safety & Tolerability • Efficacy 30 mcg 30 mcg (

  36. Slide 36: Human safety and early efficacy data in ADOA

    Human safety and early efficacy data illustrate the potential of this drug candidate in ADOA1 Human safety: Human efficacy: ADOA patients2 Change in Visual Acuity (under Low and Normal Contrast) in ADOA patients3 • No Treatment Emergent- Mean improvement in visual acuity at week 42 Serious Adverse e

  37. Slide 37: PYC-001 is progressing towards a major unmet patient need

    PYC-001 is progressing towards a major unmet patient need Estimated USA Europe Japan prevalence ~6,000 patients ~6,000 patients ~2,000 patients of ADOA1,2,3 1. Yu-Wai-Man, P. et al. Ophthalmology. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. 2010;117(8):1538-46

  38. Slide 38: PYC is in the critical human data generation window

    PYC is in the critical human data generation window with a pipeline of drug candidates with disease-modifying potential 1 2 3 4 5 Disease-modifying In areas of major With the highest Validated in patient- Generating human drug candidates1 unmet need probability of success derived models data in 2026

PYC Therapeutics — Investor Presentation (January 2026) on 6ix